118 related articles for article (PubMed ID: 37598355)
1. Factors associated with CD4 + cell count recovery among males and females with advanced HIV disease.
Kouamou V; Gundidza P; Ndhlovu CE; Makadzange AT;
AIDS; 2023 Dec; 37(15):2311-2318. PubMed ID: 37598355
[TBL] [Abstract][Full Text] [Related]
2. Effects of Gender and Baseline CD4 Count on Post-Treatment CD4 Count Recovery and Outcomes in Patients with Advanced HIV Disease: A Retrospective Cohort Study.
Kouamou V; Gundidza P; Ndhlovu CE; Makadzange AT;
AIDS Res Hum Retroviruses; 2023 Jul; 39(7):340-349. PubMed ID: 36924288
[TBL] [Abstract][Full Text] [Related]
3. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa.
Kroeze S; Ondoa P; Kityo CM; Siwale M; Akanmu S; Wellington M; de Jager M; Ive P; Mandaliya K; Stevens W; Boender TS; de Pundert ME; Sigaloff KCE; Reiss P; Wit FWNM; Rinke de Wit TF; Hamers RL
AIDS; 2018 May; 32(8):1043-1051. PubMed ID: 29547445
[TBL] [Abstract][Full Text] [Related]
4. CD4+ cell count recovery after initiation of antiretroviral therapy in HIV-infected Ethiopian adults.
Fiseha T; Ebrahim H; Ebrahim E; Gebreweld A
PLoS One; 2022; 17(3):e0265740. PubMed ID: 35324948
[TBL] [Abstract][Full Text] [Related]
5. Trends in and correlates of CD4+ cell count at antiretroviral therapy initiation after changes in national ART guidelines in Rwanda.
Mutimura E; Addison D; Anastos K; Hoover D; Dusingize JC; Karenzie B; Izimukwiye I; Mutesa L; Nsanzimana S; Nash D;
AIDS; 2015 Jan; 29(1):67-76. PubMed ID: 25562492
[TBL] [Abstract][Full Text] [Related]
6. CD4+ cell count recovery following initiation of HIV antiretroviral therapy in older childhood and adolescence.
Simms V; Rylance S; Bandason T; Dauya E; McHugh G; Munyati S; Mujuru H; Rowland-Jones SL; Weiss HA; Ferrand RA
AIDS; 2018 Sep; 32(14):1977-1982. PubMed ID: 29927784
[TBL] [Abstract][Full Text] [Related]
7. Long-term HIV treatment outcomes and associated factors in sub-Saharan Africa: multicountry longitudinal cohort analysis.
Inzaule SC; Kroeze S; Kityo CM; Siwale M; Akanmu S; Wellington M; de Jager M; Ive P; Mandaliya K; Stevens W; Steegen K; Nankya I; Boender TS; Ondoa P; Sigaloff KCE; de Wit TFR; Hamers RL
AIDS; 2022 Aug; 36(10):1437-1447. PubMed ID: 35608116
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal analysis of sociodemographic, clinical and therapeutic factors of HIV-infected individuals in Kinshasa at antiretroviral therapy initiation during 2006-2017.
Ngongo NM; Darcis G; Nanituna HS; Mambimbi MM; Maes N; Mashi ML; Bepouka Izizag B; Moutschen M; Lepira Bompeka F
PLoS One; 2021; 16(11):e0259073. PubMed ID: 34739506
[TBL] [Abstract][Full Text] [Related]
9. Time to eligibility for antiretroviral therapy in adults with CD4 cell count > 500 cells/μL in rural KwaZulu-Natal, South Africa.
McGrath N; Lessells RJ; Newell ML
HIV Med; 2015 Sep; 16(8):512-8. PubMed ID: 25959724
[TBL] [Abstract][Full Text] [Related]
10. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.
O'Connor J; Vjecha MJ; Phillips AN; Angus B; Cooper D; Grinsztejn B; Lopardo G; Das S; Wood R; Wilkin A; Klinker H; Kantipong P; Klingman KL; Jilich D; Herieka E; Denning E; Abubakar I; Gordin F; Lundgren JD;
Lancet HIV; 2017 Mar; 4(3):e105-e112. PubMed ID: 28063815
[TBL] [Abstract][Full Text] [Related]
11. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
[TBL] [Abstract][Full Text] [Related]
12. Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa.
Nakanjako D; Kiragga AN; Musick BS; Yiannoutsos CT; Wools-Kaloustian K; Diero L; Oyaro P; Lugina E; Ssali JC; Kambugu A; Easterbrook P
AIDS; 2016 Jul; 30(12):1913-22. PubMed ID: 26959510
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study.
Mwesigire DM; Wu AW; Martin F; Katamba A; Seeley J
BMC Health Serv Res; 2015 Jul; 15():292. PubMed ID: 26216221
[TBL] [Abstract][Full Text] [Related]
14. A retrospective clinical study of dolutegravir- versus efavirenz-based regimen in treatment-naïve patients with advanced HIV infection in Nanjing, China.
Zhong M; Li M; Qi M; Su Y; Yu N; Lv R; Ye Z; Zhang X; Xu X; Cheng C; Chen C; Wei H
Front Immunol; 2022; 13():1033098. PubMed ID: 36700216
[TBL] [Abstract][Full Text] [Related]
15. Time to initiation of antiretroviral therapy in HIV-infected patients diagnosed with an opportunistic disease: a cohort study.
Deconinck L; Yazdanpanah Y; Gilson RJ; Melliez H; Viget N; Joly V; Sabin CA
HIV Med; 2015 Apr; 16(4):219-29. PubMed ID: 25522796
[TBL] [Abstract][Full Text] [Related]
16. High uptake of antiretroviral therapy among HIV-positive TB patients receiving co-located services in Swaziland.
Pathmanathan I; Pasipamire M; Pals S; Dokubo EK; Preko P; Ao T; Mazibuko S; Ongole J; Dhlamini T; Haumba S
PLoS One; 2018; 13(5):e0196831. PubMed ID: 29768503
[TBL] [Abstract][Full Text] [Related]
17. Impact of Age and Sex on CD4+ Cell Count Trajectories following Treatment Initiation: An Analysis of the Tanzanian HIV Treatment Database.
Means AR; Risher KA; Ujeneza EL; Maposa I; Nondi J; Bellan SE
PLoS One; 2016; 11(10):e0164148. PubMed ID: 27716818
[TBL] [Abstract][Full Text] [Related]
18. Renal dysfunction by baseline CD4 cell count in a cohort of adults starting antiretroviral treatment regardless of CD4 count in the HIV Prevention Trials Network 071 [HPTN 071; Population Effect of Antiretroviral Therapy to Reduce HIV Transmission (PopART)] study in South Africa.
Bock P; Nel K; Fatti G; Sloot R; Ford N; Voget J; Gunst C; Grobbelaar N; Louis F; Floyd S; Hayes R; Ayles H; Beyers N; Fidler S;
HIV Med; 2019 Jul; 20(6):392-403. PubMed ID: 30963667
[TBL] [Abstract][Full Text] [Related]
19. Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting.
Clouse K; Pettifor A; Maskew M; Bassett J; Van Rie A; Gay C; Behets F; Sanne I; Fox MP
AIDS; 2013 Feb; 27(4):645-50. PubMed ID: 23169326
[TBL] [Abstract][Full Text] [Related]
20. Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals.
Okulicz JF; Le TD; Agan BK; Camargo JF; Landrum ML; Wright E; Dolan MJ; Ganesan A; Ferguson TM; Smith DM; Richman DD; Little SJ; Clark RA; He W; Ahuja SK
JAMA Intern Med; 2015 Jan; 175(1):88-99. PubMed ID: 25419650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
